Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 128 versus ISOVUE 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 128 versus ISOVUE 300.
ISOVUE-128 vs ISOVUE-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.
Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.
Adult: 50-200 mL (0.5-2.0 mL/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.
Intravenous: 50-150 mL (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 mL depending on procedure; intrathecal: 8-15 mL. Maximum total iodine dose: 300 mg iodine/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours with GFR <30 mL/min).
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 mL/min), the half-life can be prolonged up to 20–40 hours, requiring dose adjustment.
Renal: >95% excreted unchanged in urine via glomerular filtration; fecal/biliary: <5%.
Primarily renal (glomerular filtration), with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% is excreted via bile/fecal route.
Category C
Category C
Contrast Media
Contrast Media